UK's Arecor Therapeutics rises on positive results for diabetes drug trial
20/05/2024 08:32
** Shares of Arecor Therapeutics AREC.L jump 6.8% to 145
pence
** The UK-based biopharma group says its ultra-concentrated,
ultra-rapid acting insulin candidate, AT278, met all goals in a
Phase I clinical trial in Type 2 diabetics with a high body mass
index
** Says AT278 demonstrated superiority to Novo Nordisk's
NOVOb.CO NovoRapid and Eli Lilly and Co's LLY.N Humulin R
U-500 in the trial
** Adds no safety signals were detected during the clinical
trial
** Stock down 28.2% YTD, as of last close
(Reporting by Echha Jain in Bengaluru)
((Echha.jain@thomsonreuters.com))